Abstract: Disclosed is a cathode active material and a method to produce the same at low cost. The cathode powder comprises modified LiCoO2, and possibly a second phase which is LiM?O2 where M? is Mn, Ni, Co with a stoichiometric ratio Ni:Mn?1. The modified LiCoO2 is Ni and Mn bearing and has regions of low and high manganese content, where regions with high manganese content are located in islands on the surface. The cathode material has high cycling stability, a very high rate performance and good high temperature storage properties.

Abstract: Thin nano structured layers on surfaces of nickel or its alloys for quickly achieving high hydrogen adsorption values (H/Ni˜0.7) through direct metal/gas contact. The said layers are produced by a process comprising the step of oxidising the said surfaces, applying a film of aqueous silica sol to them, subsequent heating in an -oxidising atmosphere and final activation through reduction in a reducing atmosphere.

Abstract: A catalyst comprising: (a) a microporous crystalline molecular sieve comprising at least silicon, aluminium and phosphorous and having an 8-ring pore size; and (b) a transition metal loaded in the molecular sieve, the transition metal loading is less than about 1 wt %.

Abstract: Dermatological methods of cosmetic, therapeutic, prophylactic, and/or diagnostic treatment by topically applying compositions comprising a multiplicity of particles, at least one of the particles comprising porous and/or polycrystalline silicon. Included are methods and compositions for sun protection applications. The use of porous silicon, polycrystalline silicon, and porous silicon oxide mirrors is disclosed.

Abstract: The invention provides a cancer therapeutic and imaging agent comprising a solution containing Gum Arabic coated 198Au nanoparticles. The Gum Arabic coated 198Au nanoparticles have been demonstrated experimentally shown to have a surprising efficacy for a single dose direct injection, reducing tumors in analog mice by 82% over a short period of time. The particles of the invention have a believed optimal size for therapy and imaging applications, and can be used as a theranostic agent in the treatment of needle accessible cancers. The invention also provides a method for forming Gum Arabic coated 198Au nanoparticles. A gold foil is irradiated to produce 198Au foil. The foil is dissolved to form radioactive gold salt. The salt is dried, and then reconstituted to form a 198Au nanoparticle precursor. The precursor is reduced with a reducing agent in an aqueous solution including Gum Arabic to form Gum Arabic coated 198Au nanoparticles.

Abstract: A method for formation of spherical particles of ion substituted calcium phosphate. The method is based on precipitation of particles from a buffered solution under static, stirring or hydrothermal conditions. Also, the use of the formed materials and the particles in itself.

Abstract: The present application discloses compositions and methods of synthesis and use of 18F or 19F-labeled molecules of use in PET, SPECT and/or MR imaging. Preferably, the 18F or 19F is conjugated to a targeting molecule by formation of a complex with a group IIIA metal and binding of the complex to a bifunctional chelating agent, which may be directly or indirectly attached to the targeting molecule. In other embodiments, the 18F or 19F labeled moiety may comprise a targetable construct used in combination with a bispecific antibody to target a disease-associated antigen. The disclosed methods and compositions allow the simple and reproducible labeling of molecules at very high efficiency and specific activity in 30 minutes or less. In preferred embodiments, the labeled molecule may be used for imaging in a subject without purification after labeling.

Abstract: This invention relates to solid compositions and solid pharmaceutical products for use in methods of photodynamic diagnosis of cancer, pre-cancerous and non-cancerous conditions in the lower part of the gastrointestinal system. The solid pharmaceutical compositions and pharmaceutical products comprise an active ingredient which is 5-aminolevulinic acid (5-ALA) or a precursor or derivative of 5-ALA or pharmaceutically acceptable salts thereof. The invention relates further to methods of photodynamic diagnosis of cancer, pre-cancerous and non-cancerous conditions of the lower gastrointestinal tract, wherein the solid pharmaceutical compositions and pharmaceutical products are used.

Abstract: Disclosed herein, in certain embodiments, is a selective transport molecule with increased in vivo circulation. In some embodiments, a selective transport molecule disclosed herein has the formula (A—X—B—C)n—M, wherein C is a cargo moiety; A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from: aspartates and glutamates; B is a peptide with a sequence comprising 5 to 20 consecutive basic amino acids; X is a linker; and M is a macromolecular carrier.

Abstract: The present invention provides a novel method of labelling biological targeting molecules (BTMs) of interest with radioiodine. Also provided are novel radioiodinated BTMs prepared using the method, as well as radiopharmaceutical compositions comprising such radioiodinated BTMs. The invention also provides radioiodinated intermediates useful in the method, as well as in vivo imaging methods using.

Abstract: Micro-vesicles that become acoustically sensitive in the presence of a Radio Frequency (RF) Electromagnetic (EM) field are presented. The micro-vesicles can comprise a main body having one or more affinity ligands configured to preferentially bind to a target tissue. Once bound, the micro-vesicles and the target tissue can be bathed in an RF EM field, which induces the target tissue or micro-vesicles to generate an acoustic signal. The micro-vesicles can also become receptive to acoustic energy. An acoustic therapeutic signal can be directed toward the target tissue and micro-vesicles, which causes therapeutic excitation of the micro-vesicles. The therapeutic excitation can include heating the target tissue, releasing a drug formulation, or other excitation. The disclosed techniques can be used with a high degree of precision to activate micro-vesicles local to the target tissue.

Abstract: The present invention relates to the uses of the protein PRG4 and therapeutic modulation thereof. In particular, the present invention relates compositions and methods utilizing PRG4 and therapeutic modulation thereof, including, use as a surgical lubricant, use in a treatment for prevention or reduction of post-surgical adhesions, use in a treatment for oral ulcerations, use as an athletic lubricating patch, use as a dermal filler, use in a treatment for dry mouth, use in a drug delivery method or composition, and use in nursing lubrication.

Abstract: The present invention provides dynamic charge state cationic polymers that are useful for delivery of anionic molecules. The dynamic charge state cationic polymers are designed to have cationic charge densities that decrease by removal of removable functional groups from the polymers. The present invention also provides interpolyelectrolyte complexes containing the polymers complexed to a polyanion. Methods for using the interpolyelectrolyte complexes to deliver anionic compounds are also provided.

Abstract: The present invention relates to an antibody directed to a beta cell marker protein, in particular to an antibody directed to the protein TMEM27.

Abstract: The present invention is directed to compositions and methods concerning terminase proteins. In particular, the present invention is directed to terminase proteins and their function in processing telomeres and double-strand breaks.

Abstract: The present invention provides a method of treating a macrophage related disease comprising administering to a subject in need thereof an effective amount of an oxidative agent or an immunosuppressive agent. The present invention also provides a method of modulating macrophage accumulation or activation comprising administering to a subject in need thereof an effective amount of an oxidative agent or an immunosuppressive agent. The oxidative agent can be chlorite or a chlorite containing compound.

Abstract: Provided are compounds and compositions of general Formula IX: E1-L-Ar-X-PA, that may be utilized in bioconjugation procedures, where Ar is a chromophore and PA is a functional group capable of being attached to any bioactive molecule of interest. The present invention provides Formulas I-III that are capable of being attached to a bioactive vector for the selective delivery of said photoactive pyrazine derivatives to a desired biological target.

Abstract: Disclosed herein, in certain embodiments, is a selective transport molecule with increased in vivo circulation. In some embodiments, a selective transport molecule disclosed herein has the formula (A-X-B-C)-M, wherein C is a cargo moiety; A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from: aspartates and glutamates; B is a peptide with a sequence comprising 5 to 20 consecutive basic amino acids; X is a linker; and M is a macromolecular carrier.

Abstract: Nanoparticles for use as magnetic resonance imaging contrast agents are described. The nanoparticles are made up of a polymeric support and a manganese-oxo or manganses-iron-oxo cluster having magnetic properties suitable of a contrast agent. The manganese-oxo clusters may be Mn-12 clusters, which have known characteristics of a single molecule magnet. The polymer support may form a core particle which is coated by the clusters, or the clusters may be dispersed within the polymeric agent.

Abstract: The invention relates to a diagnostic or therapeutic composition comprising a monomeric X-ray contrast medium containing iodine, in particular iopromide, for use in an X-ray assisted diagnosis or therapy and for the use of high doses of an X-ray contrast medium given to a patient, in particular patients with restricted kidney function.

Abstract: Alkaloid aminoester derivatives according to formula (I) and (VI) act as muscarinic receptor antagonists.

Abstract: The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.

Abstract: A tooth whitener is provided, including a water-in-oil (W/O) emulsion phase including: a discontinuous phase comprising a peroxide, a hydrophilic solvent, and a polyol, and a continuous phase comprising a glycerol monooleate, a polymer and a polyol, wherein the tooth whitener is flowable upon being applied to teeth and is solidified by the action of moisture after being applied to teeth, and then is adhered and fixed to teeth, and wherein the glycerol monooleate is in an amount of 15% to 95% by weight, based on total weight of the tooth whitener composition.

Abstract: The present invention is directed to a stable, minimal energy required self-assembling lamellar and spherulitic composition comprising: mixture water, fatty alcohol, fatty acid, salt of fatty acid, polyglyceryl fatty acid ester and oils. The present invention relates to composition that can benefit eye mildness, even distribution of sunscreen physical filters on skin and enhanced stability.

Abstract: The invention provides sunless tanning compositions for application to skin comprising an effective amount of at least one dopamine precursor, an effective amount of curcumin and a dermatologically acceptable carrier. Methods for preparation of said compositions are disclosed. When applied to the skin, the compositions may be used darken skin.

Abstract: To provide a low-viscosity water-in-oil emulsion sunscreen cosmetic composition which is extremely excellent in UV protective enhancing effect (as the protective boosting effect of the UV absorption capability thereof) over a broad UV radiation region and has superior feeling in use (smooth feeling, dry feeling, and non-sticky feeling, etc.). A water-in-oil emulsion sunscreen cosmetic composition comprising (a) from 0.01 to 10% by mass of a water-soluble polymer and (b) from 0.01 to 30% by mass of a UV absorbent, and having a viscosity of at most 10,000 mPa·s (as measured with a B-type viscometer at 30° C.), wherein the aqueous phase accounts for at most 45% by mass.

Abstract: The invention provides process for making water-soluble nano-dispersions of water-insoluble materials in a water-soluble carrier material comprising the steps of: (i) providing a single phase mixture of: (a) a non-aqueous solvent or a mixture of miscible non-aqueous solvents, (b) at least one carrier material soluble in non-aqueous solvent (a), said carrier material being also soluble in water and solid at ambient temperature, (c) at least one water-insoluble payload material which is soluble in non-solvent (a), and, (ii) drying the mixture to remove solvent (a) and thereby obtain the carrier material (b) in solid form with payload (c) dispersed therein as nanoparticles, wherein the product of the drying step is water dispersible to give an aqueous solution of (b) and an aqueous nano-dispersion of (c).

Abstract: The invention relates to a method for smoothing out the skin by filling in recessed portions of the skin, said method comprising filling the recessed portions by means of a filling-in product which has an elastic modulus of greater than 20 000 Pascals at 25° C. for a stress frequency of 1 Hertz, a flow point of greater than 500 Pascals, and, for applied stresses of less than the yield stress, a viscosity of greater than 100000 Pa.s, the product being such that, once applied in said recessed portions of the skin, its mechanical properties change subsequent to a reaction other than an evaporation reaction or a laser polymerization re action.

Abstract: A personal care composition includes a hybrid copolymer including at least one ethylenically unsaturated monomer and a naturally derived hydroxyl containing chain transfer agent as an end group, a hybrid synthetic copolymer including one or more synthetic polymers derived from the at least one ethylenically unsaturated monomer with at least one initiator fragment as an end group and an effective amount of a cosmetic or personal care additive.

Abstract: A topical composition containing an alkoxylated diphenylacrylate compound and an aryl carboxylic ester is provided. Preferably, the topical composition is a sunscreen composition containing ?-ethylhexyl ?-cyano-?-(4-methoxyphenyl)-?-phenylacrylate and 2-phenylethyl benzoate, and optionally further containing 4,4?-t-butyl methoxydibenzoylmethane, which is characterized by improved photo-protection of the skin and is effective in preventing/reducing photo-damage of the skin upon exposure to sunlight or other sources of light in the ultraviolet (UV), visible, and infrared (IR) ranges.

Abstract: The present invention provides a compound having an excellent inhibitory action on melanin production and being useful as a whitening agent, and a skin external preparation containing the compound. The whitening agent of the present invention comprises, as an active ingredient, a heterocyclic compound represented by formula (1) or a pharmacologically acceptable salt thereof: wherein R1, R2, and R2? are each independently C1-3 alkyl; Y is S or O; and p is an integer of 0 to 3, wherein when p is 2 or 3, R1 may be the same or different.

Abstract: The present invention relates to compositions and methods for modulating melanin production, secretion and/or accumulation in human skin cells. In particular, the present invention relates to the use of A3 adenosine receptor antagonists in compositions and methods for the treatment and amelioration of hyper-pigmentation conditions and for the lightening of skin, and to the use of A3 adenosine receptor agonists in compositions and methods for the treatment and amelioration of hypo-pigmentation conditions and for the tanning of skin.

Abstract: Disclosed is a composition containing a concentrate of Korean rice wine as an active ingredient. The composition exhibits antioxidant and whitening effects, and thus can be variously used in the fields of cosmetics, functional food or medicine.

Abstract: A personal care product comprises an antiperspirant product that is housed within a container. The antiperspirant product includes a first portion comprising a dispersed cooling sensation agent. A second portion has a composition different from the first portion and comprises a solubilizer.

Abstract: The present invention relates to the use of at least one ether guanidine of the general formula (I) and/or of a salt or hydrate thereof, in which R1?—CH2—CH2—CH2—O—R3, where R3 is a linear or branched hydrocarbon radical having 6 to 22 carbon atoms, and R2?H or an optionally branched hydrocarbon radical which has 1 to 22 C atoms and which optionally comprises double bonds, for reducing the growth of microorganisms, and to cosmetic and pharmaceutical formulations comprising at least one ether guanidine of the general formulae (I).

Abstract: This invention relates to the production of biomaterials from polymeric collagen (PC) and its seeding with cells and other components of biomaterials. Polymeric collagen is isolated from tissue, suspended in an acidic solution, and then neutralised at low temperature. The neutralised suspension is then seeded with biomaterial components, such as cells, and the polymeric collagen aggregated to form a biomaterial comprising the biomaterial components. Polymeric collagen biomaterials produced as described herein may therefore be useful in a range of tissue engineering applications.

Abstract: Adhesion-promoting, thin film, moisture resistant skin barrier formulations are composed of a fugitive solvent mixture consisting of t-butanol and an alkane fraction composed of at least one alkane, where the t-butanol is in the range of 40-70% by weight of the solvent mixture, and a film-forming solute dissolved in the fugitive solvent mixture. The formulations may also include one or more optional ingredients such as antimicrobial and/or bioactive agents. When applied to the skin, the formulations improve the adhesion of various classes of medical adhesives used to attach a variety of medical devices to the skin and create a thin, flexible and elastic continuous barrier film on the skin to protect against body fluids and incontinence.

Abstract: Provided according to some embodiments of the invention are topical gels that may release nitric oxide. Also provided are methods of using such topical gels in the treatment of wounds and other skin ailments. The topical gels comprise diazeniutndiolate-functionalized polysiloxane macromolecules.

Abstract: This invention provides a method of inactivating non-enveloped virus particles. The method includes the step of contacting the virus with a virucidally-enhanced alcoholic composition that includes an alcohol, and an enhancer selected from the group consisting of cationic oligomers and polymers, proton donors, chaotropic agents, and mixtures thereof.

Abstract: Anti-microbial compositions including an anti-microbial polymer containing silicon-containing quaternary ammonium groups, polyvinyl alcohol (PVA), at least one short chain alcohol, optional fragrance, and water are provided. The anti-microbial compositions may be used to disinfect both porous and non-porous surfaces. Exemplary compositions may include 0.1-10 wt % of the anti-microbial polymer containing silicon-containing quaternary ammonium groups, 0.1-10 wt % polyvinyl alcohol (PVA), 1.0-20 wt % isopropyl alcohol, optional fragrance, and water.

Abstract: The present invention relates to a vaccine for increasing the immunogenicity of a tumor antigen thus allowing treatment of cancer, as well as a vaccine that increases the immunogenicity of a viral antigen, thus allowing treatment of viral infection, including immunodeficiency virus (HIV) infection. In particular, the present invention provides a fusion protein comprising a defensin fused to either a tumor antigen or viral antigen which is administered as either a protein or nucleic acid vaccine to elicit an immune response effective in treating cancer or effective in treating or preventing viral infection.

Abstract: The invention is to provide a novel anticancer agent or sensitizer for cancer chemotherapy or radiotherapy. A compound of a general formula (I): wherein A means an aryl group or a heteroaryl group, or a group of a formula (a):; R1 means a —(C?O)aOb(C1-C6)alkyl group, a —(C?O)aOb(C2-C6)alkenyl group, a —(C?O)aOb(C3-C6)cycloalkyl group, an aryl group or a heteroaryl group; R2 and R3 each mean a hydrogen atom, a halogen atom, a hydroxyl group, a carboxyl group, a —(C?O)aOb(C1-C6)alkyl group or a group of —(C?O)aN(R1e)R2e; R4 means a hydrogen atom or a (C1-C6)alkyl group, and the like have an excellent Wee 1-kinase-inhibitory effect, and are therefore useful in the field of medicine, especially in the field of various cancer treatments.

Abstract: The present invention comprises compositions and methods for delivery systems of agents, including therapeutic compounds, pharmaceutical agents, drugs, detection agents, nucleic acid sequences and biological factors. In general, these vector compositions comprise a colloidal metal, derivatized PEG (polyethylene glycol) and an agent. The invention also comprises methods and compositions for making such colloidal metal compositions and for treatment of cancer.

Abstract: The present invention relates to a purified nucleic acid sequence encoding a homologue of human interleukin 10 (IL-10), wherein said IL-10 homologue is expressed during the latent phase of infection by a virus of the herpesvirideae group. The present invention also relates to uses of this polypeptide, in particular for diagnosing disease states and screening for modulator and inhibitor compounds of such polypeptides and in turn the virus itself, screening for infection in vertebrates and biological tissue, cleansing of infected biological tissues, and in the treatment and/or prophylaxis and/or diagnosis of disease caused by a virus of the herpesvirideae group.

Abstract: The invention provides compositions containing hydroxyethyl starch and polypeptides, including therapeutic polypeptides such as interleukin-11, that provide for enhanced stability of the polypeptide following storage at room temperature or elevated temperatures.

Abstract: The invention relates to pyrimidine compounds of the Formula I: or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds.

Abstract: A recombinant human interferon-alpha mutein that contains at least one glycosylation site at a position of its amino acid sequence that is a part of an alpha helix-type secondary structure, a gene encoding the mutein, a method for producing the gene, a method for obtaining an eukaryotic cell producing the mutein, a method for producing the mutein, a process for purifying the mutein, a pharmaceutical composition containing the mutein, and the use of the mutein for manufacturing a medicament.

Abstract: Disclosed is an interferon-? (IFN-?) fused protein having IFN-? fused to a cytoplasmic transduction peptide (CTP). The disclosure relates to a fused protein wherein a CTP, which binds well to cell-membrane barriers and enables translocation into the liver, is genetically fused to a human IFN-?, thereby enhancing the conjugation capacity of cell membranes and antiviral activity, inhibiting CTP transport into the cell nucleus, and enhancing the translocation and settlement of the fused protein into the liver and of transduction to the liver tissue. Accordingly, it is possible to develop protein-based medicines effective for preventing or treating various liver diseases associated with viral infection at low doses.

Abstract: Disclosed is a method of treating a wound comprising applying a composition to a wound site on a patient in need of wound treatment, wherein the composition comprises mitotically inactive allogeneic cells that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGF?, angiopoietin, EGF, IL-I?, IL-6, IL-8, TGF?, and TNF?, and wherein the cells are keratinocytes or fibroblasts, or mixtures thereof.

Abstract: Provided are viral sensitizing compounds that enhance the efficacy of viruses by increasing spread of the virus in cells, increasing the titer of virus in cells, or increasing the cytotoxicity of virus to cells. Other uses, compositions and methods of using same are also provided.